Acumen Pharmaceuticals Income Statement (2020-2026) | ABOS

Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter)
2.25M1.80M5.67M5.99M7.32M8.31M10.75M8.71M9.13M11.18M13.29M12.45M19.53M27.25M34.57M25.27M37.12M21.97M20.53M16.48M
Selling, General & Administrative (Quarter)
1.19M2.13M2.74M3.22M3.09M3.06M3.50M4.42M4.34M4.86M5.19M5.33M4.85M5.02M5.03M5.10M4.62M4.54M4.67M4.67M
Operating Expenses (Quarter)
3.44M3.94M8.41M9.21M10.41M11.37M14.25M13.13M13.48M16.04M18.49M17.77M24.38M32.27M39.60M30.37M41.75M26.51M25.20M21.15M
Operating Income (Quarter)
-3.44M-3.94M-8.41M-9.21M-10.41M-11.37M-14.25M-13.13M-13.48M-16.04M-18.49M-17.77M-24.38M-32.27M-39.60M-30.37M-41.75M-26.51M-25.20M-21.15M
EBIT (Quarter)
-3.44M-3.94M-8.41M-9.21M-10.41M-11.37M-14.25M-13.13M-13.48M-16.04M-18.49M-17.77M-24.38M-32.27M-39.60M-30.37M-41.75M-26.51M-25.20M-21.15M
Non-operating items
Interest & Investment Income (Quarter)
0.00M0.04M1.88M3.12M3.95M4.00M3.82M3.50M2.99M2.47M2.02M1.64M1.32M1.06M
Other Non Operating Income (Quarter)
0.02M0.02M0.00M0.00M-0.00M-0.01M-0.00M-0.02M-0.05M-0.07M-0.01M-1.19M0.19M-0.04M-0.07M-0.20M0.46M
Non Operating Income (Quarter)
0.00M0.01M0.06M0.08M0.26M0.66M1.38M1.83M1.87M3.08M1.99M2.90M3.84M2.50M2.44M1.57M0.80M0.06M0.06M0.41M
Net income details
EBT (Quarter)
-55.06M-3.92M-8.39M-9.24M-22.91M-51.19M-14.13M-13.18M-11.63M-12.91M-14.70M-14.77M-21.57M-29.79M-36.55M-28.92M-40.78M-25.94M-24.96M-21.15M
Profit After Tax (Quarter)
-61.36M-3.90M-8.58M-9.71M-10.15M-10.71M-12.87M-11.31M-11.73M-12.96M-16.50M-15.33M-20.56M-29.77M-37.72M-28.73M-40.95M-26.36M-25.16M-20.80M
Income from Non-Controlling Interests (Quarter)
-0.03M-0.20M-0.58M-0.15M0.21M0.23M-0.12M0.14M0.82M-0.46M-0.02M0.68M-0.57M0.06M0.01M0.09M-0.03M-0.06M
Income from Continuing Operations (Quarter)
-55.06M-3.92M-8.39M-9.24M-22.91M-51.19M-14.13M-13.18M-11.63M-12.91M-14.70M-14.77M-21.57M-29.79M-36.55M-28.92M-40.78M-25.94M-24.96M-21.15M
Consolidated Net Income (Quarter)
-55.06M-3.92M-8.39M-9.24M-22.91M-51.19M-14.13M-13.18M-11.63M-12.91M-14.70M-14.77M-21.57M-29.79M-36.55M-28.92M-40.78M-25.94M-24.96M-21.15M
Income towards Parent Company (Quarter)
-55.06M-3.92M-8.39M-9.24M-22.91M-51.19M-14.13M-13.18M-11.63M-12.91M-14.70M-14.77M-21.57M-29.79M-36.55M-28.92M-40.78M-25.94M-24.96M-21.15M
Net Income towards Common Stockholders (Quarter)
-55.06M-3.92M-8.39M-9.24M-22.91M-51.19M-14.13M-13.18M-11.63M-12.91M-14.70M-14.77M-21.57M-29.79M-36.55M-28.92M-40.78M-25.94M-24.96M-21.15M
Additional items
EPS (Basic) (Quarter)
-127.36-0.10-0.42-0.23-0.57-1.26-0.35-0.32-0.28-0.24-0.30-0.25-0.36-0.50-0.61-0.48-0.67-0.43-0.41-0.33
EPS (Diluted) (Quarter)
-127.36-0.10-0.42-0.23-0.57-1.26-0.35-0.32-0.28-0.24-0.30-0.25-0.36-0.50-0.61-0.48-0.67-0.43-0.41-0.33
Shares Outstanding (Quarter)
0.43M38.27M20.06M40.47M40.50M40.50M40.60M41.03M41.03M54.23M48.61M59.81M60.08M60.08M60.01M60.53M60.57M60.57M60.56M63.22M
Shares Outstanding (Diluted) (Quarter)
0.43M38.27M20.06M40.47M40.50M40.50M40.60M41.03M41.03M54.23M48.61M59.81M60.08M60.08M60.01M60.53M60.57M60.57M60.56M63.22M
EBITDA (Quarter)
-3.44M-3.94M-8.41M-9.21M-10.41M-11.37M-14.25M-13.13M-13.48M-16.04M-18.49M-17.77M-24.38M-32.27M-39.60M-30.37M-41.75M-26.51M-25.20M-21.15M
Interest Expenses (Quarter)
51.62M0.02M-0.02M0.04M12.50M39.82M-0.11M0.04M0.04M0.17M1.00M1.00M1.03M-0.06M1.02M1.05M1.07M1.09M1.07M